Cholestech Corporation Announces Promotion of Robert J. Dominici to Chief Operating Officer -- Diagnostic Products.

HAYWARD, Calif.--(BW HealthWire)--Dec. 1, 1999--

Cholestech Corporation (Nasdaq:CTEC) today announced that Robert J. Dominici has agreed to take on additional responsibility as Chief Operating Officer for the company's Diagnostic Products business unit.

Dominici will remain Executive Vice President of the Corporation with overall responsibility for the operations, sales, marketing and development functions of the Diagnostic Products business.

Commenting on Dominici's promotion, Warren E. Pinckert II, President and Chief Executive Officer said, "Over the last year, Bob and his team have added effective new programs to Cholestech's sales and marketing efforts. His extensive background in the diagnostics market, strong industry knowledge, and general management experience make him the ideal person to head up Cholestech's Diagnostic Products business."

Dominici joined Cholestech in 1998 from Boehringer Mannheim Corporation (currently Roche Boehringer Mannheim), a $900 million U.S. division of Boehringer Mannheim Diagnostics, focused on point of care diagnostics, monitoring of diabetes, automated diagnostic laboratory systems and research biochemicals. During his thirteen plus years at Boehringer Mannheim Corporation, Dominici held numerous senior executive positions, including: President of Boehringer's Laboratory Diagnostics Systems Division, President and CEO of Microgenics Corporation (a wholly owned subsidiary), and Senior Vice President and General Manager for Corporate Accounts.

About Cholestech

Cholestech is committed to helping people successfully improve their health. Working together, the Cholestech business units of WellCheck, WellCheck.com, and Diagnostic Products, can provide simple, accessible, and reliable personal health information to health care practitioners and directly to consumers in over 35 countries around the world.

By offering efficient and economic diagnostic screening for cholesterol, blood sugar, and liver function, Cholestech hopes to help more people understand whether or not they face potentially serious health risks. Therapeutic monitoring options using the Cholestech L.D.X(R) System can help patients monitor their progress as they work with their health care provider to reduce their risk of cardiovascular and other diseases. Working together with health care providers, Cholestech's goal is to ultimately enable people to lead longer, healthier, and more active lives.

Safe Harbor Statement of Cholestech Corporation under the Private

Securities Litigation Reform Act of 1995:

This release may contain forward-looking statements based on Cholestech's current expectations, estimates, and projections about its industry, management's beliefs, and certain assumptions made by Cholestech. Words such as "anticipates," "expects," "intends," "plans," "believes," "may," "will," and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this release include statements regarding the ability of Cholestech's Diagnostic Products, WellCheck, and WellCheck.com businesses to successfully provide personal health management and help identify potential health risks and monitor therapy. These statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict. Therefore Cholestech's actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

There are several major risks created by Cholestech's pursuit of its new strategy. These risks include the following:

Cholestech has no experience in the Testing Services or Internet Businesses. The testing services business and the Internet business to be pursued through its newly created WellCheck and WellCheck.com businesses are completely new to Cholestech and its management team. To date Cholestech's business has been exclusively in the area of manufacturing and marketing the Cholestech L.D.X(R) System. Cholestech may not be able to successfully develop these new businesses. The demands of attempting to grow these new businesses may prevent Cholestech from devoting significant time and attention to its traditional business, and that traditional business may decline.

Internet Health Management is a new and unproven Business. The internet-based health information management business is a very new and as yet unproven market. Whether Cholestech succeeds in this business will depend upon individual acceptance of internet-based management of personal health information. People may not feel comfortable having their health-related information available over the Internet despite the privacy and security measures Cholestech plans to take.

Cholestech has minimal experience in managing geographically diverse operations. Cholestech's traditional business has been managed and operated almost exclusively from its Hayward, California headquarters. The new WellCheck business Cholestech is adopting will require Cholestech to operate in multiple geographic locations. This will require Cholestech to manage multiple, geographically dispersed businesses and adapt its management and financial systems and controls to this new geographically dispersed business. Cholestech may not be able to manage these changes rapidly, successfully, or at all.

Significant Startup Expenses. The development of the two new business units, and the WellCheck.com Internet business in particular, will require significant start-up expenditures. These expenditures are likely to materially effect the operating results of Cholestech as a whole. The Company may need to seek additional capital to help fund these start-up expenses. The required additional capital may not be available to Cholestech on favorable or acceptable terms when required, or at all. If Cholestech cannot obtain required additional capital, Cholestech may have to change its business strategy, which would be disruptive to its business. If Cholestech raises additional capital through borrowings, the terms of such borrowings may impose limitations on how its management may operate the business in the future. If Cholestech raises additional capital by issuing equity, this may result in a dilution of existing shareholders' interests in Cholestech. Also, equity issued by Cholestech may have rights, preferences, or privileges senior to those of Cholestech's existing shareholders.

Acquisition Related Risks. The WellCheck business will be developed in significant part by Cholestech's acquiring existing testing service businesses. Cholestech may acquire services and/or technology to assist in developing its WellCheck.com business as well. Any such acquisition could result in significant amounts of cash, potentially dilutive issuances of equity securities, and/or the incurring of debt or amortization expenses related to goodwill and other intangible assets, any of which could materially harm Cholestech's operating results and business.

-0-

Additional risks from the acquisition(s) Cholestech plans may include:

--   Difficulties in assimilating the operations, technologies,
     products, services, and personnel of the acquired company or
     business -- especially assimilating multiple small businesses
     that Cholestech may acquire.

--   The diversion of Cholestech's management's attention from other
     business concerns; and

--   The potential loss of key employees of the acquired company or
     business.

-0-

Internet Business Risks. Cholestech's planned WellCheck.com business will involve the provision and management of individual health-related information over the Internet. Despite security measures Cholestech plans to take, such information may be accessed or manipulated by third parties without its or the individual's consent. Any such security breach could greatly erode consumer confidence in Cholestech's WellCheck.com business and could severely harm that business and its prospects. Additionally, if software or technical problems corrupt an individual's health information, consumer confidence in the WellCheck.com business could be severely damaged. If consumer information is altered by third parties or by technical problems, the affected individual may bring litigation against Cholestech and/or the Company's web site hosting partners. Any such litigation could result in significant expense, including any damage awards. Even if ultimately decided in Cholestech's favor, such litigation could result in significant expense and distraction of its management.

Cholestech's recent Annual Report of Form 10-K and Quarterly Report on Form 10-Q and other Securities and Exchange Commission filings discuss some of the important risk factors that may effect its business, results of operations, and financial condition. Cholestech undertakes no obligation to revise or update publicly any forward-looking statements for any reason. All such forward-looking statements are current only as of the date on which such statements were made.

Note to Editors: Cholestech L.D.X(R), WellCheck, and WellCheck.com are registered trademarks of Cholestech Corporation. For more information about Cholestech and its products visit us on the web at www.cholestech.com.